Mitochondrial dysfunction and energy changes of black-substance neurons in experimental parkinson's disease in rats and mothors
DOI:
https://doi.org/10.34287/MMT.3(50).2021.5Abstract
Parkinson's disease is a progressive disease with moderate age of the beginning of 55 years. Over time, symptoms worsen, and although levodopa has significantly improved the quality of life of patients with PD, statistics show that these patients continue to show shorter life expectancies compared to the general population. In addition, most patients with PD suffer from significant movement disorders after 5–10 years of illness, even with qualified treatment with available symptomatic drugs.
References
Sveinbjornsdottir S. The clinical symptoms of Parkinson's disease. J Neurochem. 2016 Oct; 139 Suppl 1:318-324. doi: 10.1111/jnc.13691. Epub 2016 Jul 11. PMID: 27401947.
Opara J, Małecki A, Małecka E, Socha T. Motor assessment in Parkinson`s disease. Ann Agric Environ Med. 2017 Sep 21; 24 (3): 411 − 415. doi: 10.5604/12321966.1232774. Epub 2017 May 11. PMID: 28954481.
Lotankar S, Prabhavalkar KS, Bhatt LK. Biomarkers for Parkinson's Disease: Recent Advancement. Neurosci Bull. 2017 Oct; 33 (5): 585−597. doi: 10.1007/s12264-017-0183-5. Epub 2017 Sep 21. PMID: 28936761; PMCID: PMC5636742.
Cabreira V, Massano J. Doença de Parkinson: Revisão Clínica e Atualização [Parkinson's Disease: Clinical Review and Update]. Acta Med Port. 2019 Oct 1; 32 (10): 661−670. Portuguese. doi: 10.20344/amp.11978. PMID: 31625879.
Cacabelos R. Parkinson's Disease: From Pathogenesis to Pharmacogenomics. Int J Mol Sci. 2017 Mar 4;18(3):551. doi: 10.3390/ijms18030551. PMID: 28273839; PMCID: PMC5372567.
Falkenburger BH, Saridaki T, Dinter E. Cellular models for Parkinson's disease. J Neurochem. 2016 Oct; 139 Suppl 1: 121−130. doi: 10.1111/ jnc.13618. Epub 2016 Apr 18. PMID: 27091001.
Bose A, Beal MF. Mitochondrial dysfunction in Parkinson's disease. J Neurochem. 2016 Oct; 139 Suppl 1: 216−231. doi: 10.1111/jnc.13731. Epub 2016 Aug 21. PMID: 27546335.
Nguyen M, Wong YC, Ysselstein D, Severino A, Krainc D. Synaptic, Mitochondrial, and Lysosomal Dysfunction in Parkinson's Disease. Trends Neurosci. 2019 Feb; 42 (2): 140−149. doi: 10.1016/j.tins.2018.11.001. Epub 2018 Nov 30. PMID: 30509690; PMCID: PMC6452863.
Rocha EM, De Miranda B, Sanders LH. Alphasynuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson's disease. Neurobiol Dis. 2018 Jan;109(Pt B): 249− 257. doi: 10.1016/j.nbd.2017.04.004. Epub 2017 Apr 8. PMID: 28400134.
Burbulla LF, Song P, Mazzulli JR, Zampese E, Wong YC, Jeon S, Santos DP, Blanz J, Obermaier CD, Strojny C, Savas JN, Kiskinis E, Zhuang X, Krüger R, Surmeier DJ, Krainc D. Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease. Science. 2017 Sep 22; 357 (6357): 1255−1261. doi: 10.1126/science.aam9080. Epub 2017 Sep 7. PMID: 28882997; PMCID: PMC6021018.
Subramaniam SR, Chesselet MF. Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Prog Neurobiol. 2013 Jul-Aug; 106−107: 17−32. doi: 10.1016/j. pneurobio.2013.04.004. Epub 2013 Apr 30. PMID: 23643800; PMCID: PMC3742021.
Li H, Ham A, Ma TC, Kuo SH, Kanter E, Kim D, Ko HS, Quan Y, Sardi SP, Li A, Arancio O, Kang UJ, Sulzer D, Tang G. Mitochondrial dysfunction and mitophagy defect triggered by heterozygous GBA mutations. Autophagy. 2019 Jan; 15 (1): 113−130. doi: 10.1080/15548627.2018.1509818. Epub 2018 Oct 12. PMID: 30160596; PMCID: PMC6287702.
Larsen SB, Hanss Z, Krüger R. The genetic architecture of mitochondrial dysfunction in Parkinson's disease. Cell Tissue Res. 2018 Jul; 373 (1): 21−37. doi: 10.1007/s00441-017-2768-8. Epub 2018 Jan 25. PMID: 29372317; PMCID: PMC6015629.
Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE. Parkinson disease. Nat Rev Dis Primers. 2017 Mar 23; 3: 17013. doi: 10.1038/nrdp.2017.13. PMID: 28332488.
Park JS, Davis RL, Sue CM. Mitochondrial Dysfunction in Parkinson's Disease: New Mechanistic Insights and Therapeutic Perspectives. Curr Neurol Neurosci Rep. 2018 Apr 3; 18 (5): 21. doi: 10.1007/s11910-018-0829-3. PMID: 29616350; PMCID: PMC5882770.
Macdonald R, Barnes K, Hastings C, Mortiboys H. Mitochondrial abnormalities in Parkinson's disease and Alzheimer's disease: can mitochondria be targeted therapeutically? Biochem Soc Trans. 2018 Aug 20;46(4):891-909. doi: 10.1042/ BST20170501. Epub 2018 Jul 19. PMID: 30026371.
Ryan BJ, Hoek S, Fon EA, Wade-Martins R. Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease. Trends Biochem Sci. 2015 Apr; 40 (4): 200−10. doi: 10.1016/j.tibs.2015.02.003. Epub 2015 Mar 8. PMID: 25757399.
Raza C, Anjum R, Shakeel NUA. Parkinson's disease: Mechanisms, translational models and management strategies. Life Sci. 2019 Jun 1; 226: 77−90. doi: 10.1016/j.lfs.2019.03.057. Epub 2019 Apr 10. PMID: 30980848.
Pozo Devoto VM, Falzone TL. Mitochondrial dynamics in Parkinson's disease: a role for α-synuclein? Dis Model Mech. 2017 Sep 1; 10 (9): 1075−1087. doi: 10.1242/dmm.026294. PMID: 28883016; PMCID: PMC5611962.
